{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:58:18Z","timestamp":1769309898825,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH","award":["R01CA122930"],"award-info":[{"award-number":["R01CA122930"]}]},{"name":"NIH","award":["R35CA197725"],"award-info":[{"award-number":["R35CA197725"]}]},{"name":"NIH","award":["R01NS093903"],"award-info":[{"award-number":["R01NS093903"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.omto.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T02:15:30Z","timestamp":1494036930000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model"],"prefix":"10.1016","volume":"5","author":[{"given":"Julius W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Miska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Robert","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech K.","family":"Panek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina V.","family":"Balyasnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2017.05.001_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4155\/tde.14.123","article-title":"Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy","volume":"6","author":"Spencer","year":"2015","journal-title":"Ther. Deliv."},{"issue":"Suppl 2","key":"10.1016\/j.omto.2017.05.001_bib2","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/neuonc\/nou355","article-title":"Sui generis: gene therapy and delivery systems for the treatment of glioblastoma","volume":"17","author":"Kane","year":"2015","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.omto.2017.05.001_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fonc.2013.00032","article-title":"Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice","volume":"3","author":"Auffinger","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2017.05.001_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/cns.13.35","article-title":"Oncolytic virotherapy for gliomas: steps toward the future","volume":"2","author":"Kaufmann","year":"2013","journal-title":"CNS Oncol."},{"key":"10.1016\/j.omto.2017.05.001_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.cgt.7701080","article-title":"A phase I trial of intravenous infusion of ONYX-015 and Enbrel in solid tumor patients","volume":"14","author":"Nemunaitis","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2017.05.001_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.cgt.7700988","article-title":"Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver","volume":"14","author":"Au","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2017.05.001_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/978-1-59745-561-9_35","article-title":"Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas","volume":"542","author":"Opyrchal","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2017.05.001_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.gt.3302436","article-title":"Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas","volume":"12","author":"Galanis","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2017.05.001_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2017.05.001_bib10","first-page":"5277","article-title":"A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin","volume":"16","author":"Kimball","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2017.05.001_bib11","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2017.05.001_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12967-016-0895-8","article-title":"Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters","volume":"14","author":"Kim","year":"2016","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omto.2017.05.001_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"key":"10.1016\/j.omto.2017.05.001_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1099\/0022-1317-45-2-455","article-title":"Replication and interaction of virus DNA and cellular DNA in mouse cells infected by a human adenovirus","volume":"45","author":"Younghusband","year":"1979","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omto.2017.05.001_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/jvi.46.1.50-59.1983","article-title":"Control of adenovirus gene expression: cellular gene products restrict expression of adenovirus host range mutants in nonpermissive cells","volume":"46","author":"Katze","year":"1983","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2017.05.001_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10409238609082543","article-title":"Control of cellular and viral transcription during adenovirus infection","volume":"19","author":"Nevins","year":"1986","journal-title":"CRC Crit. Rev. Biochem."},{"key":"10.1016\/j.omto.2017.05.001_bib17","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in\u00a0vivo and in cultures of primary cells from different animal species","volume":"80","author":"Jogler","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2017.05.001_bib18","doi-asserted-by":"crossref","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2017.05.001_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2007.002","article-title":"Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma","volume":"18","author":"Ulasov","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2017.05.001_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000066361.02042.CA","article-title":"Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets","volume":"76","author":"Contreras","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.omto.2017.05.001_bib21","doi-asserted-by":"crossref","first-page":"e1022302","DOI":"10.1080\/2162402X.2015.1022302","article-title":"Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T\u00a0cell therapy","volume":"4","author":"Qiao","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2017.05.001_bib22","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.02032-10","article-title":"Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity","volume":"85","author":"Jiang","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2017.05.001_bib23","doi-asserted-by":"crossref","first-page":"e0153814","DOI":"10.1371\/journal.pone.0153814","article-title":"Critical role of autophagy in the processing of adenovirus capsid-incorporated cancer-specific antigens","volume":"11","author":"Klein","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2017.05.001_bib24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T\u00a0cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2017.05.001_bib25","doi-asserted-by":"crossref","first-page":"e955697","DOI":"10.4161\/21624011.2014.955697","article-title":"The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity","volume":"3","author":"Kleijn","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2017.05.001_bib26","doi-asserted-by":"crossref","first-page":"e97495","DOI":"10.1371\/journal.pone.0097495","article-title":"The in\u00a0vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity","volume":"9","author":"Kleijn","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omto.2017.05.001_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2017.05.001_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccell.2014.10.008","article-title":"CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance","volume":"26","author":"Zitvogel","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2017.05.001_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.20061890","article-title":"In\u00a0vivo imaging of cytotoxic T\u00a0cell infiltration and elimination of a solid tumor","volume":"204","author":"Boissonnas","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2017.05.001_bib30","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-09-1067","article-title":"Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines","volume":"15","author":"Ueda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2017.05.001_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/CJI.0b013e318155a0f6","article-title":"In\u00a0vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma","volume":"30","author":"Wu","year":"2007","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omto.2017.05.001_bib32","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2017.05.001_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7150\/jca.10640","article-title":"Immune suppression during oncolytic virotherapy for high-grade glioma; yes or no?","volume":"6","author":"Koks","year":"2015","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.omto.2017.05.001_bib34","doi-asserted-by":"crossref","DOI":"10.1055\/s-0034-1397203","article-title":"Virotherapy overcomes tumor resistance to PD-1-immunotherapy by broad mutanome-directed T\u00a0cell responses in mice","volume":"53","author":"Woller","year":"2015","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.omto.2017.05.001_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"key":"10.1016\/j.omto.2017.05.001_bib36","doi-asserted-by":"crossref","first-page":"18133","DOI":"10.1038\/srep18133","article-title":"A novel single-chain antibody redirects adenovirus to IL13R\u03b12-expressing brain tumors","volume":"5","author":"Kim","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770517300207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770517300207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:18:48Z","timestamp":1762496328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770517300207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":36,"alternative-id":["S2372770517300207"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2017.05.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s).","name":"copyright","label":"Copyright"}]}}